ESMO 2023 | eNRGy: zenocutuzumab in NRG1 fusion-positive NSCLC

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses results from the Phase II eNRGy trial (NCT02912949), which is assessing the safety, tolerability and anti-tumor activity of the bispecific antibody zenocutuzumab in patients with NRG1 fusion-positive solid tumors. Here, she discusses the results of the non-small cell lung cancer (NSCLC) cohort of patients. Zenocutuzumab exhibited a well-tolerated safety profile, with Grade 3 or higher adverse events occurring in fewer than 4% of patients, as well as a promising overall response rate. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.